Kerry O. Cleveland, MD

Professor
University of Tennessee Health Science Center

Disclosure(s): AbbVie: Honoraria; Cumberland: Honoraria; Merck: Honoraria; Pfizer: Honoraria

Poster(s):

• 897 - Criteria Restricting Inappropriate Meropenem Empiricism (CRIME): A Quasi-Experimental Carbapenem Restriction Pilot at a Large Academic Medical Center
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 1017 - Residual Infusion Performance Evaluation (RIPE): A Single-Center Evaluation of Residual Volume Post-Intravenous Eravacycline Infusion
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 2231 - Assessing Clinical Cure of Empiric Piperacillin-Tazobactam for ESBL Urinary Tract Infections (ACCEPT-UTI)
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET